IP Library Granted Patent US 12692299
Granted Patent B2
US 12692299 · App. 18/172,258 · Granted Jul 28, 2026

Variant ICOS ligand immunomodulatory proteins and related compositions and methods

Inventors: Lawrence Evans (Seattle, WA); Michael Kornacker (Seattle, WA); Ryan Swanson (Seattle, WA)
Assignee: Alpine Immune Sciences, Inc.
C07K14/70532A61K35/54A61K38/1774A61K40/11A61K40/22A61K40/31A61K40/418A61K40/4205A61K40/421A61K40/4211C12N5/0681C12N15/85C12P21/02A61K2239/31C07K2319/02C07K2319/03C07K2319/21C07K2319/30C07K2319/31C07K2319/41C07K2319/43
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12692299
App. No.
18/172,258
Granted
Jul 28, 2026
Kind
B2
Abstract

Provided herein are immunomodulatory proteins comprising ICOSL variants and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.

Claims (6)

1 . A nucleic acid molecule encoding a variant ICOSL-Fc fusion protein comprising a variant ICOSL polypeptide linked via a linker to an Fc region, wherein the variant ICOSL polypeptide is set forth in SEQ ID NO:565, the linker is set forth in SEQ ID NO:229, and the Fc region is set forth in SEQ ID NO:637.

2 . An expression vector comprising the nucleic acid molecule of claim 1 .

3 . A cell comprising the nucleic acid molecule of claim 1 .

4 . A method of producing a variant ICOSL-Fc fusion protein, the method comprising introducing the nucleic acid molecule of claim 1 into a host cell under conditions to express the protein in the cell, and purifying the expressed protein.

5 . The method of claim 4 , wherein the cell is a CHO cell or a derivative thereof.

6 . The method of claim 5 , wherein the CHO cell or derivative thereof is a CHO DG44 cell.